– KVD900 Phase 2 HAE Trial Data Expected in 2019 – – KVD824 Named as Next Oral Plasma Kallikrein Inhibitor to Enter Clinic – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jan. 4, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the...